IIT Gandhinagar Funds Anti-microbial Air Purifier Start-up with Rs50L - Vibes Of India

Gujarat News, Gujarati News, Latest Gujarati News, Gujarat Breaking News, Gujarat Samachar.

Latest Gujarati News, Breaking News in Gujarati, Gujarat Samachar, ગુજરાતી સમાચાર, Gujarati News Live, Gujarati News Channel, Gujarati News Today, National Gujarati News, International Gujarati News, Sports Gujarati News, Exclusive Gujarati News, Coronavirus Gujarati News, Entertainment Gujarati News, Business Gujarati News, Technology Gujarati News, Automobile Gujarati News, Elections 2022 Gujarati News, Viral Social News in Gujarati, Indian Politics News in Gujarati, Gujarati News Headlines, World News In Gujarati, Cricket News In Gujarati

IIT Gandhinagar Funds Anti-microbial Air Purifier Start-up with Rs50L

| Updated: April 14, 2022 18:23

IIT Gandhinagar Innovation and Entrepreneurship Center (IIEC) today announced that it had lent its support to indigenous anti-microbial air purifier start-up, Airth Research Private Limited, with a seed fund of Rs50 lakh. In fact, IIEC said that it has already released the first installment of Rs25 lakhs. This funding was provided under under the Nidhi4Covid2.0 programme of Department of Science and Technology (DST) that encourages innovative solutions and products made in India in order to fight against COVID-19.

Airth Research is expected to utilize this fund to develop a household version of its anti-microbial air purifier, which can reduce and deactivate the germs, including Coronavirus-sized particles, by 99.99%. The company, founded by Ravi Kaushik, an alumnus of IIT Bombay, is involved in developing such anti-microbial air purifiers and have already made versions for large spaces. These big purifiers are currently being used by early adapters such as RBI office in Mumbai, SHCIL, and ONGC, among others.

Sharing his thoughts on receiving the funding from IIEC, Kaushik said, “It has been great to receive support from IIEC. Because of this funding, we were able to deliver our products to a cancer hospital, and now we are able to contribute to saving the lives of immunocompromised patients in that hospital. To multi-fold our impact, we will scale up our manufacturing as well.”

Your email address will not be published. Required fields are marked *

%d